

## **Annex I**

**Scientific conclusions and grounds for the variation to the terms of the Marketing  
Authorisation(s)**

### **Scientific conclusions**

Taking into account the PRAC Assessment Report on the PSUR(s) for acitretin, the scientific conclusions are as follows:

In view of available data on psychiatric disorders from the literature, spontaneous reports and in view of a possibly shared mechanism of action with other retinoids, the PRAC considers a causal relationship between acitretin and 'altered mood' and 'psychotic disorder' is at least a reasonable possibility. The PRAC concludes that the product information of products containing acitretin should be amended accordingly.

Having reviewed the PRAC recommendation, the CMDh agrees with the PRAC overall conclusions and grounds for recommendation.

### **Grounds for the variation to the terms of the marketing authorisation(s)**

On the basis of the scientific conclusions for acitretin the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing acitretin is unchanged subject to the proposed changes to the product information.

The CMDh recommends that the terms of the marketing authorisation(s) should be varied.

## **Annex II**

**Amendments to the product information of the nationally authorised medicinal product(s)**

**Amendments to be included in the relevant sections of the Product Information** (new text underlined and in bold, deleted text ~~strike through~~)

*The wording below is to be adapted, at a national level, to the existing wordings in the product information. In case the product information already includes a more precise wording, the more precise wording should remain.*

## Summary of Product Characteristics

- Section 4.4

Psychiatric disorders

Depression, depression aggravated, anxiety, ~~and~~ mood alterations and psychotic disorder have been reported in patients treated with systemic retinoids, including acitretin. Particular care should be taken in patients with a history of depression. Patients should be monitored for signs of depression and referred for appropriate treatment if necessary. Awareness by family or friends may be useful to detect mental health deterioration.

- Section 4.8

The following adverse reaction(s) should be added under the SOC Psychiatric disorders with the frequency 'Not known':

### Altered mood

### Psychotic disorder

## Package Leaflet

- Section 2 Warnings and precautions

Additional precautions

[...]

Talk to your doctor before taking <tradenam>:

- If you have ever had any mental health problems including depression, aggressive tendencies, ~~or~~ mood changes or signs of psychosis (altered sense of reality, such as hearing voices or seeing things that are not there). This is because taking <tradenam> may affect your mood and mental health.

- Section 4 Possible side effects

The following adverse reaction(s) should be included with a frequency 'Not known':

[...]

Other side effects:

Not known (frequency cannot be estimated from the available data):

### Altered mood

Signs of psychosis: altered sense of reality, such as hearing voices or seeing things that are not there.

### **Annex III**

**Timetable for the implementation of this position**

**Timetable for the implementation of this position**

Adoption of CMDh position:	May 2024 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	14 July 2024
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	12 September 2024